GE Healthcare, Geron Expand Deal for Stem Cell-based Assays | GenomeWeb

NEW YORK (GenomeWeb News) – GE Healthcare said today it has expanded its licensing agreement with Geron for the development of cellular assays and models derived from embryonic stem cells.

The assays and models are for use in drug discovery and toxicity screening, and under the terms of the expanded deal, GE has exclusive rights to Geron's IP and know-how for developing and selling cellular assays derived from induced pluripotent stem cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.